Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK comparison of twice-daily tacrolimus vs once-daily extended-release tacrolimus (LCPT) in diabetic transplant recipients
2019-003602-27Phase 4Completed
- Sponsor
- CHU de Nantes
- Start
- Jan 2020
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in diabetes mellitus type 1 (T1D), chronic kidney disease (CKD) and immunocompromise, sponsored by CHU de Nantes. Primary endpoint: AUC0-24. Started Jan 2020; status: completed.
02
Drugs
tacrolimus
03
Conditions
diabetes mellitus type 1 (T1D)chronic kidney disease (CKD)immunocompromise
Beyond the preview
Go deeper on 2019-003602-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003602-27.